Geneva, Switzerland, December 18, 2019 – Abologix is profiled in the leading swiss Business magazine “Bilan” as one of the most promissing start ups in Suisse Romande. The company has been invited to present its investment case in a future event sponsored by “Bilan” to be held in Lausanne, Switzerland.
top of page
Geneva, Switzerland, December 23, 2024 – Abologix has been awarded 100,000 CHF by the KICK FUND to progress its advanced preclinical...
Geneva, Switzerland, November 23, 2023 – Abologix successfully completes the Innosuisse-funded program for the initial characterization...
Geneva, Switzerland, December 20, 2022 – Abologix nominates monoclonal antibody H225 (blocker of JAM-C, Junction Adhesion Molecule C) as...
bottom of page
Comments